IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
August 30 2021 - 7:00AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company focused on the discovery and development of innovative
gamma-delta T-cell therapies utilizing its DeltEx platform, today
announced that William Ho, President, Chief Executive Officer and
co-founder of IN8bio, will present at the NewYorkBIO Virtual
Breakfast Series and the virtual H.C. Wainwright 23rd Annual Global
Investment Conference.
Event: |
NewYorkBIO
Virtual Breakfast Series |
Date: |
August 31 |
Presentation: |
Webinar – Fireside Chat |
Time: |
August 31st at 9 am EDT |
Link: |
https://bit.ly/3DkM2Rn |
|
|
Event: |
H.C. Wainwright 23rd Annual Global Investment Conference |
Date: |
September 13-14th |
Presentation: |
Video presentation |
Time: |
Available starting September 13th at 7 am EDT |
Link: |
https://bit.ly/3jlRaMQ |
Webcasts of the presentations can also be accessed through the
Events & Presentations section of the Company's website
at https://investors.in8bio.com/news-events/events-presentations.
The H.C Wainwright presentation will be available for approximately
90 days following the release of the video presentation.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T-cell product candidates for
solid and liquid tumors. Gamma-delta T-cells are a specialized
population of T-cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T-cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
leukemia undergoing hematopoietic stem cell transplantation. IN8bio
also has a broad portfolio of preclinical programs focused on
addressing other solid tumor types.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio, Inc.Kate Rochlin,
Ph.D.+1 646.600.6GDT (6438)info@IN8bio.com
Investors:Solebury TroutNicholas Colangelo + 1
646.378.2929ncolangelo@troutgroup.com
Media:Burns McClellan, Inc.Robert Flamm, Ph.D.
/ Harrison Wong+1 212.213.0006 - ext. 364 / 316rflamm@burnsmc.com /
hwong@burnsmc.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Sep 2024 to Oct 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Oct 2023 to Oct 2024